Inventor
EFREMOV IVAN VIKTOROVICH
US31 patents
⚠️ This page may combine multiple inventors who share the name “EFREMOV IVAN VIKTOROVICH”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
PFIZER
22 patentsUS9663526B2May 30, 2017
Aminopyrimidinyl compounds
PFIZER22 citations93
US9527831B2Dec 27, 2016
Heteroaromatic compounds and their use as dopamine D1 ligands
PFIZER13 citations92
US9139561B2Sep 22, 2015
Heteroaromatic compounds and their use as dopamine D1 ligands
PFIZER8 citations92
US9107923B2Aug 18, 2015
Heteroaromatic compounds and their use as dopamine D1 ligands
PFIZER11 citations92
US9133190B2Sep 15, 2015
Heteroaromatic compounds and their use as dopamine D1 ligands
PFIZER8 citations84
US8822494B2Sep 2, 2014
Heteroaromatic compounds and their use as dopamine D1 ligands
PFIZER12 citations84
US10093655B2Oct 9, 2018
Heteroaromatic compounds and their use as dopamine D1 ligands
PFIZER3 citations83
US9822097B2Nov 21, 2017
Heteroaromatic compounds and their use as dopamine D1 ligands
PFIZER6 citations83
US9688698B2Jun 27, 2017
Heteroaromatic compounds and their use as dopamine D1 ligands
PFIZER4 citations73
US9527843B2Dec 27, 2016
Heteroaromatic compounds and their use as dopamine D1 ligands
PFIZER3 citations73
US11197867B2Dec 14, 2021
Aminopyrimidinyl compounds
PFIZER2 citations72
US10980815B2Apr 20, 2021
Aminopyrimidinyl compounds
PFIZER2 citations72
US10463675B2Nov 5, 2019
Aminopyrimidinyl compounds
PFIZER4 citations72
US10421744B2Sep 24, 2019
Heteroaromatic compounds and their use as dopamine D1 ligands
PFIZER2 citations72
US9617275B2Apr 11, 2017
Heteroaromatic compounds and their use as dopamine D1 ligands
PFIZER5 citations68
US11964961B2Apr 23, 2024
Heteroaromatic compounds and their use as dopamine D1 ligands
PFIZER0 citations62
US11014909B2May 25, 2021
Heteroaromatic compounds and their use as dopamine D1 ligands
PFIZER0 citations62
US9856263B2Jan 2, 2018
Heteroaromatic compounds and their use as dopamine D1 ligands
PFIZER2 citations62
US10077272B2Sep 18, 2018
Heteroaromatic compounds and their use as dopamine D1 ligands
PFIZER0 citations52
US9868744B2Jan 16, 2018
Heteroaromatic compounds and their use as dopamine D1 ligands
PFIZER1 citations52
US9745317B2Aug 29, 2017
Heterocyclic compounds and their use as dopamine D1 ligands
PFIZER1 citations52
US10696658B2Jun 30, 2020
Heteroaromatic compounds and their use as dopamine D1 ligands
PFIZER0 citations51
CYSTIC FIBROSIS FOUND THERAPEUTICS INC
4 patentsUS10208053B2Feb 19, 2019
Bicyclic heteroaryl derivatives as CFTR potentiators
CYSTIC FIBROSIS FOUND THERAPEUTICS INC31 citations92
US10131670B2Nov 20, 2018
Bicyclic heteroaryl derivatives as CFTR potentiators
CYSTIC FIBROSIS FOUND THERAPEUTICS INC27 citations92
US10377762B2Aug 13, 2019
Bicyclic heteroaryl derivatives as CFTR potentiators
CYSTIC FIBROSIS FOUND THERAPEUTICS INC1 citations71
US10301315B2May 28, 2019
Pyrrolopyrimidines as CFTR potentiators
CYSTIC FIBROSIS FOUND THERAPEUTICS INC1 citations61
FULCRUM THERAPEUTICS INC
3 patentsUS10973805B2Apr 13, 2021
Macrocyclic azolopyridine derivatives as EED and PRC2 modulators
FULCRUM THERAPEUTICS INC5 citations81
US11590111B2Feb 28, 2023
Macrocyclic azolopyridine derivatives as EED and PRC2 modulators
FULCRUM THERAPEUTICS INC2 citations70
US12109198B2Oct 8, 2024
Macrocyclic azolopyridine derivatives as EED and PRC2 modulators
FULCRUM THERAPEUTICS INC0 citations59